Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding toVEGF(165) and VEGF(165)center dot KDR complexes

Citation
Y. Hamma-kourbali et al., Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding toVEGF(165) and VEGF(165)center dot KDR complexes, J BIOL CHEM, 276(43), 2001, pp. 39748-39754
Citations number
47
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF BIOLOGICAL CHEMISTRY
ISSN journal
00219258 → ACNP
Volume
276
Issue
43
Year of publication
2001
Pages
39748 - 39754
Database
ISI
SICI code
0021-9258(20011026)276:43<39748:VEGF1(>2.0.ZU;2-4
Abstract
We have previously shown that carboxymethyl dextran benzylamide (CMDB7), a heparin-like molecule, inhibits the growth of tumors xenografted in nude mi ce, angiogenesis, and metastasis by altering the binding of angiogenic grow th factors, including platelet-derived growth factor, transforming growth f actor beta, and fibroblast growth factor 2, to their specific receptors. In this study, we explore the effect of CMDB7 on the most specific angiogenic growth factor, vascular endothelial growth factor 165 (VEGF(165)). We demo nstrate here that CMDB7 inhibits the mitogenic effect of VEGF(165) on human umbilical vein endothelial cells (HUV-ECs) by preventing the VEGF(165)-ind uced VEGF receptor-2 (KDR) autophosphorylation and consequently a specific intracellular signaling. In competition experiments, the binding of I-125-V EGF(165) to HUV-ECs is inhibited by CMDB7 with an IC50 of 2 muM. Accordingl y, CMDB7 inhibits the cross-linking of I-125-VEGF(165), to the surface of H UV-ECs, causing the disappearance of both labeled complexes, 170-180 and 24 0-250 kDa. We show that CMDB7 increases the electrophoretic mobility of VEG F165, thus evidencing formation of a stable complex with this factor. Moreo ver, CMDB7 reduces the I-125-VEGF(165) binding to coated heparin-albumin an d prevents a heparin-induced increase in iodinated VEGF(165) binding to sol uble I-125-KDR-Fc chimera. Concerning KDR, CMDB7 has no effect on I-125-KDR -Fc electrophoretic migration and does not affect labeled KDR-Fc binding to coated heparin-albumin. In the presence of VEGF(165), I-125-KDR-Fc binding to heparin is enhanced, and under these conditions, CMDB7 interferes with KDR binding. These data indicate that CMDB7 effectively inhibits the VEGF(1 65) activities by interfering with heparin binding to VEGF(165) and VEG(165 ).KDR complexes but not by direct interactions with KDR.